Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment

Current Psychiatry Reports

Volumn 18, Issue 9, 2016, Pages

  Tondo, Leonardo ^a,b,c   Baldessarini, Ross J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

^c Centro Lucio Bini   (Italy)

Author keywords

Anticonvulsants; Antidepressants; Antipsychotics; Bipolar I and II disorders; Lithium; Major depressive disorder; Suicide

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; SEDATIVE AGENT; VALPROIC ACID; PSYCHOTROPIC AGENT;

AGGRESSION; AGITATION; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CHRONIC DRUG ADMINISTRATION; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DYSPHORIA; EVIDENCE BASED MEDICINE; HUMAN; IMPULSIVENESS; MAJOR DEPRESSION; MANIA; MENTAL INSTABILITY; MOOD DISORDER; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; TREATMENT RESPONSE; BEHAVIOR; CLASSIFICATION; DRUG THERAPY; MOOD DISORDERS; PROCEDURES; PSYCHOLOGY; RISK ASSESSMENT; SUICIDAL IDEATION; SUICIDE; TREATMENT OUTCOME;

BEHAVIORAL SYMPTOMS; DRUG THERAPY; HUMANS; MOOD DISORDERS; PSYCHOTROPIC DRUGS; RISK ADJUSTMENT; SUICIDAL IDEATION; SUICIDE; TREATMENT OUTCOME;

EID: 84983638389     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-016-0715-0     Document Type: Review

References (128)

1. Hennen J, Baldessarini RJ. Reduced suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res. 2005;73:139–45.
2. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82–91. Controlled trial of clozapine vs. olanzapine for suicidal risk in schizophrenia.
3. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased suicidal risk during long-term lithium treatment: meta-analysis. Bipolar Disord. 2006;8:625–39. Meta-analysis of studies of lithium vs. suicidal risks.
4. Tondo L, Baldessarini RJ. Suicide in bipolar disorder. In: Yildiz A, Nemeroff C, Ruiz P, editors. The Bipolar Book: History, Neurobiology, and Treatment. New York: Oxford University Press; 2015. p. 509–28. Book reviews bipolar disorder comprehensively.
5. Tondo L, Lepri B, Baldessarini RJ. Suicidal status during antidepressant treatment in 789 Sardinian patients with major affective disorder. Acta Psychiatr Scand. 2008;118:106–15.
6. Kessler RC, Berglund P, Borges G, Nock M, Wang PS. Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990–1992 to 2001–2003. JAMA. 2005;293:2487–95. Epidemiology of suicide-related behaviors in the general population.
7. Nordstrom P, Samuelsson M, Åsberg M. Survival analysis of suicide risk after attempted suicide. Acta Psychiatr Scand. 1995;91:336–40.
8. Tondo L, Baldessarini RJ. Suicidal risks among 2826 major affective disorder patients. Acta Psychiatr Scand. 2007;116:419–28. Systematic comparison of risks in bipolar I, II, and unipolar mood disorder patients.
9. Tondo L, Baldessarini RJ. Reduction of suicidal behavior in bipolar disorder patients during long-term treatment with lithium. In: Koslow SH, Ruiz P, Nemeroff CB, editors. A concise guide to understanding suicide. Cambridge: Cambridge University Press; 2014. p. 217–28. Book reviews many aspects of suicide.
10. Simon RI, Hales RE. Textbook of suicide assessment and management. 2nd ed. Washington, DC: American Psychiatric Press; 2012. Basic textbook on suicide.
11. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11–53. Classic review of associations of suicide risk with specific psychiatric disorders.
12. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 5th revision (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.
13. Swann AC, Lafer B, Perugi G, Frye MA, Bauer M, Bahk WM, et al. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry. 2013;170:31–42.
14. Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: review and meta-analysis of the evidence. Bipolar Disord. 2010;12:1–9. Indicates special risks with mixed-states.
15. Tondo L, Pompili M, Forte A, Baldessarini RJ. Suicide attempts in bipolar disorders: comprehensive review of 101 reports. Acta Psychiatr Scand. 2016;133:174–86. Systematic review of the topic.
16. ISTAT. I suicidi in Italia. ISTAT; 2012. Accesible at: http://www.istat.it/it/archivio/68812. Access: 11 Apr 2016.
17. Kaplan KJ, Harrow M, Clews K. The twenty-year trajectory of suicidal activity among post-hospital psychiatric men and women with mood disorders and schizophrenia. Arch Suicide Res 2016.
18. Roy-Byrne PP, Post RM, Hambrick DD, Leverich GS, Rosoff AS. Suicide and course of illness in major affective disorder. J Affect Disord. 1988;15:1–8.
19. Schaffer A, Isometsä ET, Tondo L, Moreno DH, Sinyor M, Kessing LV, et al. Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: part I of a report of the International Society for bipolar disorders Task Force on Suicide in Bipolar Disorder. Aust N Z J Psychiatry. 2015;49:785–802. Comprehensive review of suicide in bipolar.
20. Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18:143–57.
21. Rihmer A, Gonda X, Balazs J, Faludi G. Importance of depressive mixed states in suicidal behaviour. Neuropsychopharmacol Hung. 2008;10:45–9.
22. Saunders KE, Hawton K. Clinical assessment and crisis intervention for the suicidal bipolar disorder patient. Bipolar Disord. 2013;15:575–83.
23. APA (American Psychiatric Association). Practice guideline for the assessment and treatment of patients with suicidal behaviors. Am J Psychiatry. 2003;160:1–60. A balanced and comprehensive overview.
24. Goldsmith SK, Pellmar TC, Kleinman AM, Bunney Jr WE. Reducing suicide. Washington, DC: Institute of Medicine of the US National Academies of Science; 2002. Comprehensive, medically-oriented review of suicide.
25. Weinger RD. Practice of electroconvulsive therapy: recommendations for treatment, training, and privileging: Task Force Report of the American Psychiatric Association. 2nd ed. Washington, DC: American Psychiatric Press; 2002.
26. CDC (US Centers for Disease Control and Prevention). Injury Prevention & Control: Data & Statistics (WISQARSTM). 2012. Retrieved from http://www.cdc.gov/injury/wisqars/leading_causes_death.html (April 11, 2016).
27. Ernst CL, Bird SA, Goldberg JF, Ghaemi SN. Prescription of psychotropic medications for patients discharged from a psychiatric emergency service. J Clin Psychiatry. 2010;67:720–6.
28. Baldessarini RJ, Salvatore P, Khalsa HM, Gebre-Medhin P, Imaz H, González-Pinto A, et al. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord. 2010;12:264–70.
29. De Dios C, Ezquiaga E, Garcia A, Soler B, Vieta E. Time spent with symptoms in a cohort of BD outpatients in Spain: prospective, 18-month follow-up study. J Affect Disord. 2010;125:74–81.
30. Forte A, Baldessarini RJ, Tondo L, Vázquez GH, Pompili M, Girardi P. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Affect Disord. 2015;178:71–8. Meta-analytic review indicating high levels of unresolved depressive morbidity in treated bipolar I, II, and unipolar mood disorders.
31. Isometsä ET, Henriksson MM, Aro HM, Heikkinen ME, Kuoppasalmi KI, Lönnqvist JK. Suicide in major depression. Am J Psychiatry. 1994;151:530–6.
32. Sareen J, Isaak C, Katz LY, Bolton J, Enns MW, Stein MB. Promising strategies for advancement in knowledge of suicide risk factors and prevention. Am J Prev Med. 2014;47:S257–63.
33. Sheehan D, Giddens J. Suicidality: a roadmap for assessment and & treatment. Tampa: Harm Research Press; 2015.
34. Brenner LA, Breshears RE, Betthauser LM, Bellon KK, Holman E, Harwood JE, et al. Implementation of a suicide nomenclature within two VA healthcare settings. J Clin Psychol Med Settings. 2011;18:116–28.
35. Crosby AE, Ortega LV, Melanson C. Self-directed violence surveillance: uniform definitions and recommended data elements. Version 1.0. Atlanta: Centers for Disease Control and Prevention National Center for Injury Prevention and Control Division of Violence Prevention; 2011.
36. FDA (US Food and Drug Administration). Guidance for Industry. Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2012. Accessible at: www.fda.gov/downloads/Drugs/Guidances/UCM225130.pdf.
37. Baldessarini RJ. Chemotherapy in psychiatry. 3rd ed. New York: Springer Press; 2013.
38. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials with SRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160:790–2.
39. Khan A, Khan SR, Hobus J, Faucett J, Mehra V, Giller EL, et al. Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: role of lithium levels. J Psychiatr Res. 2011;45:1489–96.
40. Sim K, Lau KL, Sim J, Sum MY, Baldessarini RJ. Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. Intl J Neuropsychopharmacol. 2015;19. Systematic review of long-term treatment trials in major depression.
41. Søndergård L, Kvist K, Lopez AG, Andersen PK, Kessing LV. Temporal changes in suicide rates for persons treated and not treated with antidepressants in Denmark during 1995–1999. Acta Psychiatr Scand. 2006;114:168–76.
42. Tondo L, Isacsson G, Baldessarini RJ. Suicide in bipolar disorder: risk and prevention. CNS Drugs. 2003;17:491–511.
43. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for bipolar disorders (ISBD) collaborative update for the management of patients with bipolar disorder. Bipolar Disord. 2013;15:1–44. Expert overview of treatments for bipolar disorder.
44. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in BD: the case for caution. Bipolar Disord. 2003;5:421–33.
45. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. International Society for bipolar disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170:1249–62. Comprehensive review of the value and risks of antidepressant treatment in bipolar disorder.
46. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord. 2005;85:245–58.
47. Baldessarini RJ, Faedda GL, Hennen J. Risk of mania with serotonin reuptake inhibitors vs. tricyclic antidepressants in children, adolescents and young adults. Arch Pediatr Adolesc Med. 2005;159:298–9.
48. Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ. 2009;180:291–7. Systematic review of large databases.
49. Koukopoulos A, Koukopoulos A. Agitated depression as a mixed state and the problem of melancholia. Psychiatr Clin North Am. 1999;22:547–64
50. Maj M, Pirozzi R, Magliano L, Fiorillo A, Bartoli L. Agitated “unipolar” major depression: prevalence, phenomenology, and outcome. J Clin Psychiatry. 2006;67:712–9.
51. Popovic D, Vieta E, Azorin JM, Angst J, Bowden CL,Mosolov S, et al. Suicide attempts in major depressive episode: evidence from the BRIDGE-II-Mix study. Bipolar Disord. 2015;17:795–803.
52. Tondo L, Baldessarini RJ, Hennen J, Minnai GP, Salis P, Scamonatti L, et al. Suicide attempts in major affective disorder patients with comorbid substance use disorders. J Clin Psychiatry. 1999;60:63–9.
53. Acharya N, Rosen AS, Polzer JP, D’Souza DN, Perahia DG, Cavazzoni PA, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol. 2006;26:587–94.
54. Baldessarini RJ, Tondo L, Strombom I, Dominguez S, Fawcett J, Oquendo M, et al. Analysis of ecological studies of relationships between antidepressant utilization and suicidal risk. Harv Rev Psychiatry. 2007;15:133–45. Critical overview of evidence concerning antidepressant treatment and suicidal risks.
55. Beasley Jr CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampey Jr AH, Heilgenstein JH, et al. Fluoxetine and suicide: meta-analysis of controlled trials of treatment for depression. BMJ. 1991;303:685–92.
56. Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol. 2006;26:203–7. FDA post-hoc review of antidepressants and risks of suicidal thoughts and behaviors.
57. Tollefson GD, Rampey Jr AH, Beasley Jr CM, Enas GG, Potvin JH. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol. 1994;14:163–9.
58. Zisook S, Trivedi MH, Warden D, Lebowitz B, Thase ME, Stewart JW, et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression. J Affect Disord. 2009;117:63–73.
59. Reseland S, Bray I, Gunnell D. Relationship between antidepressant sales and secular trends in suicide rates in the Nordic countries. Br J Psychiatry. 2006;188:354–8.
60. Möller HJ. Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. World J Biol Psychiatry. 2009;10:180–95.
61. Valuck RJ, Libby AM, Anderson HD, Allen RR, Strombom I, Marangell LB, et al. Comparison of antidepressant classes and the risk and time course of suicide attempts in adults: propensity matched, retrospective cohort study. Br J Psychiatry. 2016;208:271–9.
62. Baldessarini RJ, Lau WK, Sim J, Sum MY, Sim K. Suicidal risks in reports of long-term treatment trials for major depressive disorder. Int J Neuropsychopharm 2015.
63. Braun C, Bschor T, Franklin J, Baethge C. Suicides and suicide attempts during long-term treatment with antidepressants: meta-analysis of 29 placebo-controlled studies including 6934 patients with major depressive disorder. Psychother Psychosom. 2016;85:171–9.
64. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: analysis of the FDA database. Arch Gen Psychiatry. 2000;57:311–7.
65. Laughren TP. Meeting of the Psychopharmacology Drug Advisory Committee (PDAC) concerning suicidal risk in trials of antidepressant drugs in juvenile and adult patients. 2006. Retrieved from http://www.fda.gov/ohrms/dockets/ac/06/briefing//2006-4272b1-01-fda.pdf. Access 13 Apr 2016). FDA summary of their post-hoc findings about antidepressants and suicidal risks vs. age.
66. Wise J. Antidepressants may double risk of suicide and aggression in children, study finds. BMJ. 2016;352:i545.
67. Yerevanian BI, Choi YM. Impact of psychotropic drugs on suicide and suicidal behaviors. Bipolar Disord. 2013;15:594–621.
68. Gaertner I, Gilot C, Heidrich P, Gaertner HJ. Case control study on psychopharmacotherapy before suicide committed by 61 psychiatric inpatients. Pharmacopsychiatry. 2002;35:37–43.
69. Shih HI, Lin MC, Lin CC, Hsu HC, Lee HL, Chi CH, et al. Benzodiazepine therapy in psychiatric outpatients is associated with deliberate self-poisoning events at emergency departments—a population-based nested case-control study. Psychopharmacology (Berlin). 2013;229:665–71.
70. Sun Y, Lin CC, Lu CJ, Hsu CY, Kao CH. Association between zolpidem and suicide: a nationwide population-based, case-control study. Mayo Clin Proc. 2016;91:308–15.
71. Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry. 2001;158:1449–54.
72. Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JP, Volavka J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalization due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333:224–9.
73. Haukka J, Tiihonen J, Härkänen T, Lönnqvist J. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol Drug Saf. 2008;17:686–96.
74. Ahearn EP, Chen P, Hertzberg M, Cornette M, Suvalsky L, Cooley-Olson D, et al. Suicide attempts in veterans with BD during treatment with lithium, divalproex, and atypical antipsychotics. J Affect Disord. 2013;145:77–82.
75. Vázquez GH, Tondo L, Undurraga J, Baldessarini RJ. Overview of antidepressant treatment in bipolar depression: critical commentary. Int J Neuropsychopharmacol. 2013;16:1673–85.
76. Post RM. Treatment of bipolar depression: evolving recommendations. Psychiatr Clin North Am. 2016;39:11–33.
77. Fornaro M, Stubbs B, De Berardis D, Perna G, Valchera A, Veronese N, et al. Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: systematic review and exploratory meta-analysis of placebo-controlled clinical trials. Int J Mol Sci. 2016;17:241–54. Review of emerging value of atypical antipsychotics in mood disorders.
78. Ifteni P, Correll CU, Nielsen J, Burtea V, Kane JM, Manu P. Rapid clozapine titration in treatment-refractory BD. J Affect Disord. 2014;166:168–72.
79. Li XB, Tang YL, Wang CY, de Leon J. Clozapine for treatment-resistant bipolar disorder: systematic review. Bipolar Disord. 2015;17:235–47. Overview on clozapine vs. suicide.
80. Ciapparelli A, Dell’Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic BD: a 24-month naturalistic study. J Clin Psychiatry. 2000;61:329–34.
81. Poo SX, Agius M. Atypical antipsychotics in adult bipolar disorder: current evidence and updates in the NICE guidelines. Psychiatr Danub. 2014;26 Suppl 1:322–9.
82. Ulcickas-Yood M, Delorenze G, Quesenberry Jr CP, Tsai AL, Phillips S, Willey VJ, et al. Epidemiologic study of aripiprazole use and the incidence of suicide events. Pharmacoepidemiol Drug Saf. 2010;19:1124–30.
83. Kiviniemi M, Suvisaar J, Koivumaa-Honkanen H, Häkkinen U, Isohanni M, Hakko H. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophr Res. 2013;150:274–80.
84. Reutfors J, Bahmanyar S, Jönsson EG, Brandt L, Bodén R, Ekbom A, et al. Medication and suicide risk in schizophrenia: a nested case-control study. Schizophr Res. 2013;150:416–20.
85. Toffol E, Hätönen T, Tanskanen A, Lönnqvist J, Wahlbeck K, Joffe G, et al. Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: a nationwide registry-based prospective cohort study. J Affect Disord. 2015;183:159–65.
86. Crocq MA, Naber D, Lader MH, Thibaut F, Drici M, Everitt B, et al. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. Eur Neuropsychopharmacol. 2010;20:829–38.
87. Kerwin RW, Bolonna AA. Is clozapine antisuicidal? Expert Rev Neurother. 2004;4:187–90.
88. Thomas SH, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand. 2010;122:345–55.
89. Barak Y, Mirecki I, Knobler HY, Natan Z, Aizenberg D. Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period. Psychopharmacology (Berlin). 2004;175:215–9.
90. Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69:1228–36.
91. Gentile S. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review. Pharmacotherapy. 2013;33:1087–106.
92. Houston JP, Ahl J, Meyers AL, Kaiser CJ, Tohen M, Baldessarini RJ. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. J Clin Psychiatry. 2006;67:1246–52.
93. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003;12:423–4.
94. Seemüller F, Lewitzka U, Bauer M, Meyer S, Musil R, Schennach R, et al. Relationship of akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. Pharmacopsychiatry. 2012;45:292–6.
95. Seemüller F, Schennach R, Mayr A, Musil R, Jäger M, Maier W, et al. Akathisia and suicidal ideation in first-episode schizophrenia. J Clin Psychopharmacol. 2012;32:694–8.
96. Oquendo MA, Galfalvy HC, Currier D, Grunebaum MF, Sher L, Sullivan GM, et al. Treatment of suicide attempters with bipolar disorder: randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry. 2011;168:1050–6. Rare controlled trial to test for antisuicidal effects.
97. Søndergård L, Lopez AG, Andersen PK, Kessing LV. Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disord. 2008;10:87–94.
98. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in BD during treatment with lithium and divalproex. JAMA. 2003;290:1467–73.
99. Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: data from a randomized prospective trial. Pharmacopsychiatry. 1996;29:103–7.
100. Hayes JF, Pitman A, Marston L, Walters K, Geddes JR, King M, Osborn DP. Self-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: UK population-based electronic health records study. JAMA Psychiatr. 2016. Supports an antisuicidal effect of lithium over that of other mood-stabilizers.
101. Baldessarini RJ, Tondo L. Suicidal risks during treatment of bipolar disorder patients with lithium versus anticonvulsants. Pharmacopsychiatry. 2009;42:72–5.
102. Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior. Part I: lithium, divalproex and carbamazepine. J Affect Disord. 2007;103:5–11.
103. FDA (US Food and Drug Administration). Statistical review and evaluation antiepileptic drugs and suicidality, 2008. Retrieved from http://www.fda.gov/2008-4372b1-01.pdf.
104. Ferrer P, Ballarín E, Sabaté M, Vidal X, Rottenkolber M, Amelio J, et al. Antiepileptic drugs and suicide: a systematic review of adverse effect. Neuroepidemiology. 2014;42:107–20.
105. Fountoulakis KN, Gonda X, Baghai TC, Baldwin DS, Bauer M, Blier P, et al. Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. Int J Psychiatry Clin Pract. 2015;19:158–67.
106. Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with BD. Arch Gen Psychiatry. 2009;66:1354–60.
107. Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia. 2013;54:199–203.
108. Rissanen I, Jääskeläinen E, Isohanni M, Koponen H, Ansakorpi H, Miettunen J. Use of antiepileptic or benzodiazepine medication and suicidal ideation—the Northern Finland Birth Cohort 1966. Epilepsy Behav. 2015;46:198–204.
109. Siamouli M, Samara M, Fountoulakis KN. Is antiepileptic-induced suicidality a data-based class effect or an exaggeration? A comment on the literature. Harv Rev Psychiatry. 2014;22:379–81.
110. Smith EG, Søndergård L, Lopez AG, Andersen PK, Kessing LV. Association between consistent purchase of anticonvulsants or lithium and suicide risk: longitudinal cohort study from Denmark, 1995–2001. J Affect Disord. 2009;117:162–7.
111. Smith EG, Austin KL, Kim HM, Miller DR, Eisen SV, Christiansen CL, et al. Suicide risk in Veterans Health Administration patients with mental health diagnoses initiating lithium or valproate: historical prospective cohort study. BMC Psychiatry. 2014;14:357–88.
112. Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: 40 to 44 years’ follow-up. Arch Suicide Res. 2005;9:279–300.
113. Baldessarini RJ, Tondo L. Lithium and suicidal risk. Bipolar Disord. 2008;10:114–5.
114. Müller-Oerlinghausen B, Ahrens B, Felber W. Suicide-preventive and mortality-reducing effect of lithium. In: Bauer M, Grof P, Müller-Oerlinghausen B, editors. Lithium in neuropsychiatry. London: Informa Healthcare; 2006. p. 79–192. In a comprehensive textbook on lithium.
115. Marangell LB, Dennehy EB, Wisniewski SR, Bauer MS, Miyahara S, Allen MH, et al. Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder. J Clin Psychiatry. 2008;69:916–22.
116. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.
117. Tondo L, Hennen J, Baldessarini RJ. Reduced suicide risk with long-term lithium treatment in major affective illness: meta-analysis. Acta Psychiatr Scand. 2001;104:163–72. Early review of the evidence.
118. Lauterbach E, Felber W, Müller-Oerlinghausen B, Ahrens R, Brinisch T, Meyer T, et al. Adjunctive lithium treatment in the prevention of suicidal behavior in depressive disorders: randomized, placebo-controlled, 1-year trial. Acta Psychiatr Scand. 2008;118:469–79.
119. Tondo L, Baldessarini RJ, Hennen J, Floris G, Silvetti F, Tohen M. Lithium treatment and risk of suicidal behavior in BD patients. J Clin Psychiatry. 1998;59:405–14.
120. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry. 2007;68:380–3.
121. Lewitzka U, Bauer M, Felber W, Müller-Oerlinghausen B. Antisuicidal effect of lithium: current state of research and its clinical implications for the long-term treatment of affective disorders. Nervenarzt. 2013;84:294–306. Overview on lithium vs. suicide.
122. Tondo L, Albert MJ, Baldessarini RJ. Suicide rates in relation to health-care access in the United States: an ecological study. J Clin Psychiatry. 2006;67:517–23.
123. Barraclough B. Suicide prevention, recurrent affective disorder and lithium. Br J Psychiatry. 1972;121:391–2.
124. Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des. 2006;12:2985–92.
125. Coppen A, Farmer R. Suicide mortality in patients on lithium maintenance therapy. J Affect Disord. 1998;50:261–7.
126. Manchia M, Hajek T, O’Donovan C, Deiana V, Chillotti C, Ruzickova M, et al. Genetic risk of suicidal behavior in bipolar spectrum disorder: analysis of 737 pedigrees. Bipolar Disord. 2013;15:496–506.
127. Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: mini-review. Neuropsychobiology. 2010;62:43–9. Supports an antisuicidal effect of lithium independent of mood-stabilization.
128. Kovacsics CE, Gottesman II, Gould TD. Lithium’s antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol. 2009;49:175–98. 123.